Stark Therapeutics

Stark Therapeutics

Stark Tx is changing the way the world treats chronic diseases with gene therapy.

Security Type
Min Investment
Carlsbad, CA
Offering Date
July 29, 2020
Expected Close Date
October 27, 2020
Target Raise

Company Description

We're working on a genetic based therapy to cure Type II Diabetes known as STK-AVi1.

What's your mission? How does this make you different?

I hold innovation to be the core driving force behind Stark Therapeutics. This may not sound novel, but the pharmaceutical and biotech industries have not yet applied gene editing tech to chronic conditions like T2DM. Changing the way these conditions are treated is a key goal to what we’re doing.


Type II Diabetes

Type II diabetes (T2DM) is a lifelong disease which afflicts over 30 million people in the US alone. Current treatment requires continual lifestyle changes, medical monitoring, and medication intake. While there are multiple therapeutic options, each has its drawbacks in the form of limited effectiveness, side effects, or cost. For example, metformin is a popular T2DM drug that can be effective if taken correctly. However, a cumulative analysis of 1.6 million T2DM patients found that >30% of patients discontinued metformin chiefly due to painful gastrointestinal side effects. If you can’t take effective treatments because of side effects, you really don't have a treatment at all.

Key Deal Facts

Working on a gene therapy based cure for Type II Diabetes.

Applying premiere biotech techniques (Adeno-associated virus and interference RNA technologies).

Poised to launch a study to evaluate T2DM therapy with support from Michigan State University.

Developed and produced a COVID-19 vaccine in under four weeks.

Initiated a preclinical study to evaluate the vaccine, which yielded positive results.

Raised $50K from XX for competitive "Fight the Virus" challenge.

Use of Proceeds

If $50,000 raised, proceeds go toward developing cells for basic level vaccine manufacturing, regulatory consulting, WeFunder Fees.

If $480,000 raised, proceeds go toward vaccine viral challenge study, diabetes proof of concept study, vaccine manufacturing/optimization, regulatory consulting, lab space and consumables, WeFunder Fees.

If $1,070,000 raised, proceeds go toward vaccine viral challenge study, vaccine safety study, diabetes gene therapy proof of concept study, hiring proteomics/production specialist and regulatory affairs, FDA consulting and preparation, WeFunder Fees.

Management Team / Advisory Board Bios

Anthony Stark
Developed both Stark Therapeutics’s Vaccine and type II diabetes treatment. Powers-Knapp/Chancellors scholar @ University of Wisconsin Madison.
Amount Raised : $16,972
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter